Pacylex CEO reveals Zelenirstat phase one results
Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.
Stay updated with breaking news from Michael Weickert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.
Edmonton, Alberta--(Newsfile Corp. - February 23, 2024) - Pacylex Pharmaceuticals, a biotechnology company dedicated to developing
Cancer is one of the leading causes of death worldwide, and it is estimated that 1 in 2 men and 1 in 3 women in the US will develop a version of this disease during their lifetime.
Edmonton, Alberta--(Newsfile Corp. - September 29, 2022) - Pacylex Pharmaceuticals has dosed 16 patients in the early phase clinical trials of the company's new cancer drug, PCLX-001. PCLX-001 is an N-myristoyltransferase